The Breast Cancer Program was established in 1994 and has been led by Lewis Chodosh, MD, PhD and Angela DeMichele, MD, MSCE since 2005. Members of the Breast Cancer Program are focused on understanding the underlying causes of breast cancer to improve the detection, prevention and treatment of this disease. Program members work to achieve this goal by focusing on four key thematic areas: 1) Elucidation of the molecular mechanisms of breast cancer development and progression;2) Improvements in genetic risk assessment and development of novel prevention strategies;3) Development of novel imaging approaches to improve breast cancer detection and the assessment of therapeutic response;and 4) Translation of laboratory discoveries to novel therapeutics and biomarkers of response/outcome. These scientific goals are accomplished through four thematic groups: Breast Cancer Biology, Cancer Risk Evaluation and Prevention, Breast Imaging, and Therapeutics and Biomarkers. Members are highly interactive, as reflected in their leadership of four collaborative grants, including two NCI UOIs, an NCI U24, and a Department of Defense Breast Cancer Center of Excellence. In addition to facilitating intra- and interprogrammatic collaborations, program leadership has emphasized breast cancer clinical research as a major focus, recruited external faculty who bring important new expertise to the Program, and participated in major ACC retreats that emphasize breast cancer research. The ACC's investment in clinical/clinical research efforts, particularly the Rena Rowan Breast Center, has facilitated patient-oriented research. The Breast Cancer Program consists of 16 faculty members from seven departments in the School of Medicine and School of Arts and Sciences. These members have $8,513,166 in cancer-related grant funding (annual direct costs), of which $7,729,386 is peer-reviewed and $2,510,558 is NCI-funded. During the last funding period, members of the Breast Cancer Program published 390 cancer-related papers, of which 11% were the result of intra-programmatic collaborations and 42% were the result of inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593259
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$117,845
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Dannoon, Shorouk; Ganguly, Tanushree; Cahaya, Hendry et al. (2016) Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem 59:5684-94
Kumar, Anita J; Gimotty, Phyllis A; Gelfand, Joel et al. (2016) Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. Am J Hematol 91:1107-1112
Karunamuni, Roshan; Naha, Pratap C; Lau, Kristen C et al. (2016) Development of silica-encapsulated silver nanoparticles as contrast agents intended for dual-energy mammography. Eur Radiol 26:3301-9
Vachani, Anil; Wong, Yu-Ning; Israelite, Jennifer et al. (2016) Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer. Med Care :
Ruella, Marco; Barrett, David M; Kenderian, Saad S et al. (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814-3826
Heneghan, Mallorie B; Rheingold, Susan R; Li, Yimei et al. (2016) Treatment of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 16:223-229.e2
Clark, A S; DeMichele, A; Mankoff, D (2016) HER2 imaging in the ZEPHIR study. Ann Oncol 27:555-7
Bartlett, Edmund K; Peters, Madalyn G; Blair, Anne et al. (2016) Identification of Patients with Intermediate Thickness Melanoma at Low Risk for Sentinel Lymph Node Positivity. Ann Surg Oncol 23:250-6
Walsh, Michael F; Nathanson, Katherine L; Couch, Fergus J et al. (2016) Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol 882:1-32
Zhang, Zi; Brown, Justin C; O'Malley Jr, Bert W et al. (2016) Post-treatment weight change in oral cavity and oropharyngeal squamous cell carcinoma. Support Care Cancer 24:2333-40

Showing the most recent 10 out of 848 publications